Eric M. Ammann
About
Eric M. Ammann is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Eric M. Ammann has authored 60 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 20 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Eric M. Ammann's work include Multiple Myeloma Research and Treatments (25 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (7 papers). Eric M. Ammann is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (7 papers). Eric M. Ammann collaborates with scholars based in United States, Belgium and France. Eric M. Ammann's co-authors include Stephen S. Johnston, Chia‐Wen Hsiao, Iftekhar Kalsekar, Andrew Stokes, Andrew Yoo, Ryan M. Carnahan, Jennifer G. Robinson, JoAnn E. Manson, Mark A. Espeland and Jason M. Collins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.
In The Last Decade
Eric M. Ammann
55 papers receiving 846 citations
Peers
Eric M. Ammann
Senthil K. Vasan United Kingdom
Danny M. Cohn Netherlands
Elisabeth Ejerblad Sweden
Oleh M. Akchurin United States
Anita Lloyd Canada
Alex Disney Australia
Ilia Beberashvili Israel
Lin Xie United States
Young Rim Song South Korea
Daphne H. Knicely United States
Citations per year, relative to Eric M. Ammann Eric M. Ammann (= 1×)
peers
Senthil K. Vasan
Countries citing papers authored by Eric M. Ammann
Since
Specialization
Citations
This map shows the geographic impact of Eric M. Ammann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric M. Ammann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric M. Ammann more than expected).
Fields of papers citing papers by Eric M. Ammann
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eric M. Ammann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric M. Ammann. The network helps show where Eric M. Ammann may publish in the future.
Co-authorship network of co-authors of Eric M. Ammann
This figure shows the co-authorship network connecting the top 25 collaborators of Eric M. Ammann. A scholar is included among the top collaborators of Eric M. Ammann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric M. Ammann. Eric M. Ammann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Usmani, Saad Z., Thierry Façon, Vânia Hungria, et al.. (2025). Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone (DVRd) vs Daratumumab-Lenalidomide-Dexamethasone (DRd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 25. S308–S308.
2.
Sanden, Suzy Van, et al.. (2025). CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. Value in Health. 28(12). S63–S63.
3.
Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100.
4.
Durie, Brian G.M., Shaji Kumar, Eric M. Ammann, et al.. (2024). Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data. Advances in Therapy. 41(5). 1923–1937.
5.
Ammann, Eric M., Dejan Milentijevic, Darren A. Talbot, et al.. (2023). Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US. Heliyon. 9(2). e13258–e13258.
6.
Fonseca, Rafaël, et al.. (2023). Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 23(6). 426–437.e11.
7.
Krishnan, Amrita, Ajay K. Nooka, Ajai Chari, et al.. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research. 12(6). e220186–e220186.
8.
Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2023). Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. The Oncologist. 28(5). e263–e269.
9.
Façon, Thierry, Jesús F. San Miguel, Meletios Α. Dimopoulos, et al.. (2022). Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy. 39(5). 1976–1992.
10.
Ammann, Eric M., Elizabeth A. Chrischilles, Ryan M. Carnahan, et al.. (2021). Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012). Journal of Thrombosis and Thrombolysis. 53(2). 264–272.
11.
Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2021). First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Blood. 138(Supplement 1). 118–118.
12.
Johnston, Stephen S., et al.. (2021). Association of In-Hospital Surgical Bleeding Events with Prolonged Hospital Length of Stay, Days Spent in Critical Care, Complications, and Mortality: A Retrospective Cohort Study Among Patients Undergoing Neoplasm-Directed Surgeries in English Hospitals. ClinicoEconomics and Outcomes Research. Volume 13. 19–29.
13.
Ammann, Eric M., Annette Lam, Wenze Tang, et al.. (2020). Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma. Blood. 136(Supplement 1). 25–26.
14.
Johnston, Stephen S., John M. Morton, Iftekhar Kalsekar, et al.. (2019). Using Machine Learning Applied to Real-World Healthcare Data for Predictive Analytics: An Applied Example in Bariatric Surgery. Value in Health. 22(5). 580–586.
15.
Al‐Attar, Nawwar, et al.. (2019). Impact of bleeding complications on length of stay and critical care utilization in cardiac surgery patients in England. Journal of Cardiothoracic Surgery. 14(1). 64–64.
16.
Hungria, Vânia, Déborah Martı́nez-Baños, Christian Omar Ramos Peñafiel, et al.. (2019). Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016. British Journal of Haematology. 188(3). 383–393.
17.
Ammann, Eric M., Iftekhar Kalsekar, Andrew Yoo, & Stephen S. Johnston. (2018). Validation of body mass index (BMI)‐related ICD‐9‐CM and ICD‐10‐CM administrative diagnosis codes recorded in US claims data. Pharmacoepidemiology and Drug Safety. 27(10). 1092–1100.
18.
Ammann, Eric M., Matthew T. Drake, Robert B. Wallace, et al.. (2017). Incidence of hematologic malignancy and cause‐specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation. Cancer. 123(21). 4168–4177.
19.
Ammann, Eric M., Tait D. Shanafelt, Melissa C. Larson, et al.. (2017). Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 17(12). e11–e25.
20.
Ammann, Eric M., Enrique C. Leira, Scott K. Winiecki, et al.. (2017). Chart validation of inpatient ICD-9-CM administrative diagnosis codes for ischemic stroke among IGIV users in the Sentinel Distributed Database. Medicine. 96(52). e9440–e9440.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Senthil K. Vasan Breakdown of academic impact, for papers by Danny M. Cohn Breakdown of academic impact, for papers by Elisabeth Ejerblad Breakdown of academic impact, for papers by Oleh M. Akchurin Breakdown of academic impact, for papers by Anita Lloyd Breakdown of academic impact, for papers by Alex Disney Breakdown of academic impact, for papers by Ilia Beberashvili Breakdown of academic impact, for papers by Lin Xie Breakdown of academic impact, for papers by Young Rim Song Breakdown of academic impact, for papers by Daphne H. Knicely